Eidogen-Sertanty joins MDL® Isentris® Alliance

Brings protein-structure and ligand-based informatics expertise to community of software and service vendors


San Ramon and San Diego, CA - January 30, 2007 - Eidogen-Sertanty, a San Diego-based computational drug discovery solutions provider, has joined the rapidly growing MDL® Isentris® Alliance. Eidogen-Sertanty becomes part of a wide-ranging community of informatics companies working with Elsevier MDL to offer pharmaceutical researchers and other scientists broad, integrated solutions for managing R&D workflows.

"We are very excited to collaborate with Elsevier MDL in the Isentris Alliance," said Dr. Steve Muskal, CEO of Eidogen-Sertanty. "The partnership will help research organizations provide scientists with an expanded view of discovery information by integrating ligand-based, target specific and protein structural knowledgebases."

"The joint efforts of the MDL Isentris Alliance partners enable rapid integration of specialty applications into a comprehensive research information system," said Dr. Trevor Heritage, Senior Vice President of Elsevier MDL. "Working together, leading informatics suppliers are making it easier for companies to use Isentris and open technology platforms to tailor multiple data sources and software solutions to fit their research needs."

The recently released MDL Isentris 2.0 system integrates information and applications into workflows, and provides a research environment for scientists to access internal and external data on demand, collaborate with colleagues, analyze data and gain insight to make informed decisions. Along with significant new features and performance gains, the new release includes .NET controls for rapidly developing and extending custom applications. These Isentris controls better enable partners and organizations to integrate with and leverage Isentris.

As a preferred partner in the Isentris Alliance, Eidogen-Sertanty will work with Elsevier MDL to create connections between its discovery informatics tools and the MDL Isentris system. Eidogen-Sertanty’s suite of offerings span protein-structure based tools and ligand-based tools, including the TIP Structural Knowledgebase, EVE Comparative Visualizer, Chemical Intelligence Platform (ChIP), Kinase Knowledgebase (KKB), and Activity-Reaction-Knowledge Archival system (ARK).

Eidogen-Sertanty joins leading software and consulting companies around the world (including ACD/Labs, DeltaSoft, InfoChem, InforSense, Klee, Osthus GmbH, Spotfire, Symyx and Tripos) working with Elsevier MDL to create specialized informatics solutions that combine MDL Isentris technology and offerings from different vendors to improve scientific research productivity and return on R&D investment.

###

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

About Eidogen-Sertanty
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty’s unique and powerful suite of software, databases, and drug discovery services enables customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com


About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contacts:
Steven Muskal, Ph.D.
Chief Executive Officer
Eidogen-Sertanty, Inc.
Phone: +1 858 964-2092

Jean Holt
Senior Director, Marketing & Communications
Elsevier MDL
Phone: +1 925 543-5400
j.holt@mdl.com